Specialty Pharmacy

Fluciclovine F 18 (Axumin) is a radioactive diagnostic agent that can be used to detect recurring prostate cancer.

Researchers evaluate why HIV-infected individuals have lower magnitude responses to flu vaccines.

Out-of-pocket limits significantly higher under ACA bronze and silver plans than with employer-based plans.

CRISPR/Cas9 gene editing system shows promise eliminating HIV.

Treatment delays prevent tight blood sugar control in type 2 diabetes patients.

The underlying mechanisms of the immune system may lead to new treatments for COPD and lupus.

Study findings may help determine why inflammatory bowel disease patients have a chronic type of inflammation.

Some cancer patients treated with doxorubicin will experience heart damage.

The PI3K/AKT pathway may provide a new therapeutic target for breast cancer combination therapy.

Discovering lung cancer in the early stage shows significant survival benefits.

Anxiety can cause men with prostate cancer to forgo surveillance for chemotherapy.

Top news of the week from The American Journal of Pharmacy Benefits.

Researchers found that 80% of HIV-positive patients had increased aortic inflammation after starting antiretroviral therapy.

Recent advances and updates in oncology and cancer drug development.

MAAT could assist cancer survivors with overcoming memory problems and lessen anxiety associated with memory dysfunction.

Genetic variation can cause severe acute pancreatitis from chemotherapy in patients with acute lymphoblastic leukemia (ALL).

Vegetative area levels linked to significant decreases in diabetes, chronic illnesses, high cholesterol, and hypertension.

Obinutuzumab (Gazyva) is an engineered monoclonal antibody designed to attach to the CD20 protein.

Remicade treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Lixisenatide is an investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist for adults with type 2 diabetes.

Top news of the week on Specialty Pharmacy Times.

Acute exenatide administration reduces glucose production and insulin resistance in liver tissue.

Top news of the day from across the healthcare landscape.

Organ recipients with a history of cancer were 1.5 times more likely to die early from any cause compared with organ recipients without history of cancer.

Opdivo shows overall survival benefit at the 2-year time point compared with docetaxel in advanced non-small cell lung cancer.

Annual specialty drug spending found to be 17% higher per member in the individual market compared with the employer market.

Neutron crystallography improves insight about the enzyme HIV-1 protease.

Research could lead to new treatments for amyotrophic lateral sclerosis and frontotemporal dementia.